In clinical trials, we're often laser-focused on speed to startup, but what decisions should Sponsors make now that will still matter 3, 4, or 5 years into a study? Starting Monday, March 17th, we're examining a few of the real challenges of RTSM throughout the entire trial lifecycle. Madeline Tremont (Genmab), Iain Little (Tenthpin), Ryan Keane and Chuck Harris (Korio) share practical perspectives on quality vs. speed, system flexibility, resource planning, and supporting teams throughout the clinical trial journey. Posting videos daily starting March 17th. Follow along right here on LinkedIn.
关于我们
Korio is the Randomization & Trial Supply Management (RTSM) platform designed for flexibility, quality and speed. Not just built to tackle clinical trial challenges as they come, but built to prevent them in the first place. No matter what trials you may face, Korio is prepared to handle them.
- 网站
-
https://www.korioclinical.com
KORIO的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Doylestown，PA
- 类型
- 私人持股
- 创立
- 2021
- 领域
- RTSM、IRT和Randomization and Trial Supply Management Software
地点
-
主要
获取路线
US，PA，Doylestown，18901
KORIO员工
-
Bobby Bahram
Managing Partner at Excelerate Health Ventures
-
Ryan Keane
-
Arvita Tripati, MBA
Head of Product (VP) @ Korio | Crafting product, data, and AI strategies for FDA-regulated Digital Platforms & Products | ex-LabCorp
-
Manya Zaharko
Talent Acquisition Advisor/Lead/Partner - Venture Capital | R&D | Engineering | Sales | Corporate | HealthTech |Technology | FinTech | Healthcare |…
动态
-
The relationship with your RTSM vendor matters more than you think. Iain Little, IRT Practice Lead at Tenthpin, explains why. Clinical teams are under immense pressure - does your vendor relationship make their lives easier or harder??
-
We're very happy to welcome Chelsey Kennedy to team Korio! ??
-
Our Head of Product Arvita Tripati, MBA joined WOMEN x AI (WxAI) last week to discuss effective AI implementation. At Korio, we're taking a measured approach to AI - prioritizing real-world use cases over "shiny object" implementations and ensuring proper governance around compliance and data security. Watch for our upcoming LinkedIn video series starting April 8th, where Arvita explores the practical future of AI in clinical trials.
WOMEN x AI (WxAI) at Google today was electric. Every seat filled. Every speaker: a force. And every insight? Pure gold for anyone navigating the AI x startup x venture capital world. Huge kudos to Jenny Kay Pollock and Reut Lazo for assembling such a fire lineup of women leading some of the most pivotal efforts in Silicon Valley right now. Here are a few standout moments + powerful insights that stuck with me: ?? Preetha Ram, Managing Partner, Pier 70 Ventures / INpact Fund VCs are done investing in back-of-the-napkin ideas. They want outcomes. Integration. Traction. And above all—bias-aware products people actually want to use. ?? Mahak Sharma, Head of Platform Partnerships, Gemini “Slapping AI on top of old tech doesn’t cut it.” True AI transformation means rethinking systems end to end. If you’re building—ask: how are we moving from what exists today to what could be tomorrow? ?? Sheetal Nariani Women’s health innovation is finally getting the spotlight. And women are leading the charge. It’s happening—but why did it take so long? ?? Sabira Alloo, Head of Private Equity Partnerships, Google “Data is the new oil in the AI era.” But it only matters if you know what you’re collecting and how to extract value. Bonus points for thinking agentically. ?? Holly Uber, Human-Centered Technologist Mic drop stat: Women-led startups return 38% higher on investment. The data is there. Now it’s time to change the funding behavior. TLDR? Founders: ? Know your GTM strategy ? Show adoption, prove value ? Integrate AI thoughtfully ? Understand your data ? Build something people need (And please, don’t build a house no one wants to live in.) What are you seeing in your corner of AI, healthtech, and venture? Would love to hear your thoughts, especially from: Anisha Rassai, Anshu Khurana, Jaya G., Melissa Goldate, Jedidah K (She/Her), N. Liberty White, Thuy Vu – how’s this resonating with what you’re seeing? #WomenInAI #VentureCapital #GTM
-
-
What is the RTSM vendor's support model? Chuck Harris explains why the right support model anticipates change rather than being surprised by it.
-
How can we adapt the protocol to be more RTSM system-friendly? Iain Little suggests making things "dull and repeatable" might be the most innovative approach of all.?
-
Who decides your standards? Iain Little explains why having representatives from data management, quality, and clinical teams is crucial - and why they must be empowered to make decisions.
-
Today's clinical trials require more modifications than ever before. Ryan Keane discusses why yesterday's RTSM models struggle with today's protocol complexity and unpredictable (but expected) changes.
-
We're proud to announce our new Advisory Services - bringing RTSM expertise to the earliest stages of your clinical trial planning. Why does this matter? Because protocol decisions made early can create unexpected challenges during RTSM implementation. Our experienced team doesn't just react to what we've seen before - we can anticipate how even the most complex trial designs will function in real-world scenarios. With ICH Guidelines emphasizing the importance of building quality into protocols from the start, there's never been a better time to incorporate RTSM expertise early in your process. Work with the same project managers who will support your trial from start to finish, establishing trust and familiarity before full implementation. Visit our website to schedule an intro call today: https://lnkd.in/eAdbHu8S
-
-
The true test of a great RTSM system? Its ability to receive change. Chuck Harris explains why adaptability is crucial for ensuring your technology never stands in the way of your clinical trial operations.